Loxo Oncology (LOXO) Getting Somewhat Positive Media Coverage, Study Shows

News articles about Loxo Oncology (NASDAQ:LOXO) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Loxo Oncology earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 44.7590419940853 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

A number of research firms have commented on LOXO. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday. BTIG Research reissued a “buy” rating and issued a $102.00 target price (up previously from $75.00) on shares of Loxo Oncology in a research report on Friday, September 29th. Cowen reissued a “buy” rating on shares of Loxo Oncology in a research report on Thursday, September 28th. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Citigroup restated a “buy” rating and issued a $112.00 price target (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $90.57.

Shares of Loxo Oncology (NASDAQ LOXO) traded up $1.13 on Friday, reaching $89.99. The company’s stock had a trading volume of 440,691 shares, compared to its average volume of 334,044. Loxo Oncology has a 1-year low of $36.75 and a 1-year high of $95.92. The stock has a market cap of $2,660.25, a P/E ratio of -15.44 and a beta of 2.54.

In other news, Director Orbimed Advisors Llc sold 270,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $74.26, for a total value of $20,050,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $90.00, for a total value of $450,000.00. Following the completion of the transaction, the director now owns 144,118 shares in the company, valued at $12,970,620. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,614,555 shares of company stock worth $124,567,942. Company insiders own 44.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/loxo-oncology-loxo-given-coverage-optimism-score-of-0-06.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply